Monoclonal Antibodies for Treatment of COVID-19: An Updated Review of Current Evidence
DOI:
https://doi.org/10.33084/bjop.v7i4.6365Keywords:
SARS-CoV-2, Bamlanivimab, AstraZeneca, WuhanAbstract
The emergence of COVID-19 in December 2019 spurred a global effort to develop effective medical interventions. Therapeutic monoclonal antibodies (mAbs) have emerged as a promising strategy to combat the SARS-CoV-2 virus. Several mAbs targeting the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein have received Emergency Use Authorization (EUA) for treating mild to moderate COVID-19. Additionally, human mAbs and hyperimmune plasma derived from recovered COVID-19 patients have been explored as potential therapeutic options. This review delves into the potential of mAbs for the diagnosis and treatment of COVID-19 infection. We discuss the mechanisms of action of mAbs, as well as their advantages and limitations. Furthermore, we explore the ongoing research and development efforts to optimize mAb-based therapies for COVID-19.
Downloads
References
Chauhan S. Comprehensive review of coronavirus disease 2019 (COVID-19). Biomed J. 2020;43(4):334-40. DOI: 10.1016/j.bj.2020.05.023; PMCID: PMC7263230; PMID: 32788071
Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2021;19(3):141-54. DOI: 10.1038/s41579-020-00459-7; PMCID: PMC7537588; PMID: 33024307
Bai C, Zhong Q, Gao GF. Overview of SARS-CoV-2 genome-encoded proteins. Sci China Life Sci. 2022;65(2):280-94. DOI: 10.1007/s11427-021-1964-4; PMCID: PMC8362648; PMID: 34387838
Xiaojie S, Yu L, Lei Y, Guang Y, Min Q. Neutralizing antibodies targeting SARS-CoV-2 spike protein. Stem Cell Res. 2020;50:102125. DOI: 10.1016/j.scr.2020.102125; PMCID: PMC7737530; PMID: 33341604
Torrente-López A, Hermosilla J, Navas N, Cuadros-Rodríguez L, Cabeza J, Salmerón-García A. The Relevance of Monoclonal Antibodies in the Treatment of COVID-19. Vaccines. 2021;9(6):557. DOI: 10.3390/vaccines9060557; PMCID: PMC8229508; PMID: 34073559
Castelli MS, McGonigle P, Hornby PJ. The pharmacology and therapeutic applications of monoclonal antibodies. Pharmacol Res Perspect. 2019;7(6):e00535. DOI: 10.1002/prp2.535; PMCID: PMC6923804; PMID: 31859459
Jo EK. Interplay between host and pathogen: immune defense and beyond. Exp Mol Med. 2019;51(12):1-3. DOI: 10.1038/s12276-019-0281-8; PMCID: PMC6906370; PMID: 31827066
Singh M, de Wit E. Antiviral agents for the treatment of COVID-19: Progress and challenges. Cell Rep Med. 2022;3(3):100549. DOI: 10.1016/j.xcrm.2022.100549; PMCID: PMC8831133; PMID: 35474740
Li G, Hilgenfeld R, Whitley R, De Clercq E. Therapeutic strategies for COVID-19: progress and lessons learned. Nat Rev Drug Discov. 2023;22(6):449-75. DOI: 10.1038/s41573-023-00672-y; PMCID: PMC10113999; PMID: 37076602
McManus D, Davis MW, Ortiz A, Britto-Leon C, Cruz CSD, Topal JE. Immunomodulatory Agents for Coronavirus Disease-2019 Pneumonia. Clin Chest Med. 2023;44(2):299-319. DOI: 10.1016/j.ccm.2022.11.009; PMCID: PMC9678826; PMID: 37085221
Adibzadeh S, Amiri S, Nia GE, Taleghani MR, Bijarpas ZK, Maserat N, et al. Therapeutic approaches and vaccination in fighting COVID-19 infections: A review. Gene Rep. 2022;27:101619. DOI: 10.1016/j.genrep.2022.101619; PMCID: PMC9066810; PMID: 35530725
Ren Z, Shen C, Peng J. Status and Developing Strategies for Neutralizing Monoclonal Antibody Therapy in the Omicron Era of COVID-19. Viruses. 2023;15(6):1297. DOI: 10.3390/v15061297; PMCID: PMC10302031; PMID: 37376597
Taylor PC, Adams AC, Hufford MM, de la Torre I, Winthrop K, Gottlieb RL. Neutralizing monoclonal antibodies for treatment of COVID-19. Nat Rev Immunol. 2021;21(6):382-93. DOI: 10.1038/s41577-021-00542-x; PMCID: PMC8054133; PMID: 33875867
Pantaleo G, Correia B, Fenwick C, Joo VS, Perez L. Antibodies to combat viral infections: development strategies and progress. Nat Rev Drug Discov. 2022;21(9):676-96. DOI: 10.1038/s41573-022-00495-3; PMCID: PMC9207876; PMID: 35725925
Pedrioli A, Oxenius A. Single B cell technologies for monoclonal antibody discovery. Trends Immunol. 2021;42(12):1143-58. DOI: 10.1016/j.it.2021.10.008; PMID: 34743921
Miguez-Rey E, Choi D, Kim S, Yoon S, Săndulescu O. Monoclonal antibody therapies in the management of SARS-CoV-2 infection. Expert Opin Investig Drugs. 2022;31(1):41-58. DOI: 10.1080/13543784.2022.2030310; PMCID: PMC8862171; PMID: 35164631
Both L, Banyard AC, van Dolleweerd C, Wright E, Ma JKC, Frooks AR. Monoclonal antibodies for prophylactic and therapeutic use against viral infections. Vaccine. 2013;31(12):1553-9. DOI: 10.1016/j.vaccine.2013.01.025; PMCID: PMC7115371; PMID: 23370150
Ryman JT, Meibohm B. Pharmacokinetics of Monoclonal Antibodies. CPT Pharmacometrics Syst Pharmacol. 2017;6(9):576-88. DOI: 10.1002/psp4.12224; PMCID: PMC5613179; PMID: 28653357
Hooks MA, Wade CS, Millikan Jr WJ. Muromonab CD-3: a review of its pharmacology, pharmacokinetics, and clinical use in transplantation. Pharmacotherapy. 1991;11(1):26-37. PMID: 1902291
Chiu ML, Goulet DR, Teplyakov A, Gilliland GL. Antibody Structure and Function: The Basis for Engineering Therapeutics. Antibodies. 2019;8(4):55. DOI: 10.3390/antib8040055; PMCID: PMC6963682; PMID: 31816964
Papamichael K, Lin S, Moore M, Papaioannou G, Sattler L, Cheifetz AS. Infliximab in inflammatory bowel disease. Ther Adv Chronic Dis. 2019;10: 2040622319838443. DOI: 10.1177/2040622319838443; PMCID: PMC6435871; PMID: 30937157
Ariga S. History and Future of HER2-Targeted Therapy for Advanced Gastric Cancer. J Clin Med. 2023;12(10):3391. DOI: 10.3390/jcm12103391; PMCID: PMC10219249; PMID: 37240498
Lu RM, Hwang YC, Liu IJ, Lee CC, Tsai HZ, Li HJ, et al. Development of therapeutic antibodies for the treatment of diseases. J Biomed Sci. 2020;27(1):1. DOI: 10.1186/s12929-019-0592-z; PMCID: PMC6939334; PMID: 31894001
Naqvi AAT, Fatima K, Mohammad T, Fatima U, Singh IK, Singh A, et al. Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: Structural genomics approach. Biochim Biophys Acta Mol Basis Dis. 2020;1866(1):165878. DOI: 10.1016/j.bbadis.2020.165878; PMCID: PMC7293463; PMID: 32544429
Nejat R, Torshizi MF, Najafi DJ. S Protein, ACE2 and Host Cell Proteases in SARS-CoV-2 Cell Entry and Infectivity; Is Soluble ACE2 a Two Blade Sword? A Narrative Review. Vaccines. 2023;11(2):204. DOI: 10.3390/vaccines11020204; PMCID: PMC9968219; PMID: 36851081
Jackson CB, Farzan M, Chen B, Choe H. Mechanisms of SARS-CoV-2 entry into cells. Nat Rev Mol Cell Biol. 2022;23(1):3-20. DOI: 10.1038/s41580-021-00418-x; PMCID: PMC8491763; PMID: 34611326
Beyerstedt S, Casaro EB, Rangel EB. COVID-19: angiotensin-converting enzyme 2 (ACE2) expression and tissue susceptibility to SARS-CoV-2 infection. Eur J Clin Microbiol Infect Dis. 2021;40(5):905-19. DOI: 10.1007/s10096-020-04138-6; PMCID: PMC7778857; PMID: 33389262
Focosi D, McConnell S, Casadevall A, Cappello E, Valdiserra G, Tuccori M. Monoclonal antibody therapies against SARS-CoV-2. Lancet Infect Dis. 2022;22(11):e311-26. DOI: 10.1016/s1473-3099(22)00311-5; PMCID: PMC9255948; PMID: 35803289
Romero A, Laurent C, Lebourg L, Lemée V, Hanoy M, Roy FL, et al. Anti SARS-CoV-2 Monoclonal Antibodies in Pre-Exposure or Post-Exposure in No- or Weak Responder to Vaccine Kidney Transplant Recipients: Is One Strategy Better than Another? Viruses. 2024;16(3):381. DOI: 10.3390/v16030381; PMCID: PMC10975193; PMID: 38543747
Hwang YC, Lu RM, Su SC, Chiang PY, Ko SH, Ke FY, et al. Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection. J Biomed Sci. 2022;29(1):1. DOI: 10.1186/s12929-021-00784-w; PMCID: PMC8724751; PMID: 34983527
Izadi A, Nordenfelt P. Protective non-neutralizing SARS-CoV-2 monoclonal antibodies. Trends Immunol. 2024;45(8):609-24. DOI: 10.1016/j.it.2024.06.003; PMID: 39034185
Destache CJ, Aurit SJ, Schmidt D, Erkes LP, Tierney M, Vivekanandan R. Bamlanivimab use in mild-to-moderate COVID-19 disease: A matched cohort design. Pharmacotherapy. 2021;41(9):743-7. DOI: 10.1002/phar.2613; PMCID: PMC8441667; PMID: 34328670
Chen P, Datta G, Li YG, Chien J, Price K, Chigutsa E, et al. First-in-Human Study of Bamlanivimab in a Randomized Trial of Hospitalized Patients With COVID-19. Clin Pharmacol Ther. 2021;110(6):1467-77. DOI: 10.1002/cpt.2405; PMCID: PMC8653186; PMID: 34455583
Cui Z, Wang H, Zou H, Li L, Zhang Y, Chen W. Efficacy and safety of casirivimab and imdevimab for preventing and treating COVID-19: a systematic review and meta-analysis. J Thorac Dis. 2024;16(6):3606-22. DOI: 10.21037/jtd-23-1604; PMCID: PMC11228754; PMID: 38983147
Filippo SS, Crovetto B, Bucek J, Nahass RG, Milano M, Brunetti L. Comparative Efficacy of Early COVID-19 Monoclonal Antibody Therapies: A Retrospective Analysis. Open Forum Infect Dis. 2022;9(4):ofac080. DOI: 10.1093/ofid/ofac080; PMCID: PMC8923391; PMID: 35299987
Quiros-Roldan E, Amadasi S, Zanella I, Antoni MD, Storti S, Tiecco G, et al. Monoclonal Antibodies against SARS-CoV-2: Current Scenario and Future Perspectives. Pharmaceuticals. 2021;14(12):1272. DOI: 10.3390/ph14121272; PMCID: PMC8707981; PMID: 34959672
Deeks ED. Casirivimab/Imdevimab: First Approval. Drugs. 2021;81(17):2047-55. DOI: 10.1007/s40265-021-01620-z; PMCID: PMC8556815; PMID: 34716907
O'Brien MP, Forleo-Neto E, Sarkar N, Isa F, Hou P, Chan KC, et al. Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial. JAMA. 2022;327(5):432-41. DOI: 10.1001/jama.2021.24939; PMCID: PMC8808333; PMID: 35029629
Krone M, Wagenhäuser I, Knies K, Hofmann D, Engels G, Taurines R, et al. Clinical accuracy of SARS-CoV-2 rapid antigen testing in screening children and adolescents. J Infect. 2023;86(3):256-308. DOI: 10.1016/j.jinf.2022.12.017; PMCID: PMC9767879; PMID: 36565725
Sakurai A, Marshall S, Ogasawara T, Ogasawara T, Aoka Y, Sakura H, et al. REGN-COV2 antibody cocktail in patients with SARS-CoV-2: Observational study from a single institution in Japan. J Infect Chemother. 2022;28(7):943-7. DOI: 10.1016/j.jiac.2022.03.029; PMCID: PMC8986486; PMID: 35414436
Doggrell SA. Do we need bamlanivimab? Is etesevimab a key to treating Covid-19? Expert Opin Biol Ther. 2021;21(11):1359-62. DOI: 10.1080/14712598.2021.1985458; PMCID: PMC8500303; PMID: 34555986
Vena A, Cenderello G, Balletto E, Mezzogori L, Barbone AS, Berruti M, et al. Early Administration of Bamlanivimab in Combination with Etesevimab Increases the Benefits of COVID-19 Treatment: Real-World Experience from the Liguria Region. J Clin Med. 2021;10(2):4682. DOI: 10.3390/jcm10204682; PMCID: PMC8538905; PMID: 34682805
Chen P, Behre G, Hebert C, Kumar P, Macpherson LF, Graham-Clarke PL, et al. Bamlanivimab and Etesevimab Improve Symptoms and Associated Outcomes in Ambulatory Patients at Increased Risk for Severe Coronavirus Disease 2019: Results From the Placebo-Controlled Double-Blind Phase 3 BLAZE-1 Trial. Open Forum Infect Dis. 2022;9(5):ofac172. DOI: 10.1093/ofid/ofac172; PMCID: PMC9045956; PMID: 35493124
Plichta J, Kuna P, Panek M. Monoclonal Antibodies as Potential COVID-19 Therapeutic Agents. COVID. 2022;2(5):599-620. DOI: 10.3390/covid2050045
Pinna SM, Lupia T, Scabini S, Vita D, De Benedetto I, Gaviraghi A, et al. Monoclonal antibodies for the treatment of COVID-19 patients: An umbrella to overcome the storm? Int Immunopharmacol. 2021;101(Pt A):108200. DOI: 10.1016/j.intimp.2021.108200; PMCID: PMC8479899; PMID: 34607231
Focosi D, Casadevall A, Franchini M, Maggi F. Sotrovimab: A Review of Its Efficacy against SARS-CoV-2 Variants. Viruses. 2024;16(2):217. DOI: 10.3390/v16020217; PMCID: PMC10891757; PMID: 38399991
Gupta A, Gonzalez-Rojas Y, Juarez E, Casal MC, Moya J, Falci DR, et al. Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial. JAMA. 2022;327(13):1236-46. DOI: 10.1001/jama.2022.2832; PMCID: PMC8922199; PMID: 35285853
Griffin D, McNeil C, Okusa J, Berrent D, Guo Y, Daugherty SE. Does monoclonal antibody treatment for COVID-19 impact short and long-term outcomes in a large generalisable population? A retrospective cohort study in the USA. BMJ Open. 2023;13(8):e069247. DOI: 10.1136/bmjopen-2022-069247; PMCID: PMC10414114; PMID: 37553188
Wolf J, Abzug MJ, Anosike BI, Vora SB, Waghmare A, Sue PK, et al. Updated Guidance on Use and Prioritization of Monoclonal Antibody Therapy for Treatment of COVID-19 in Adolescents. J Pediatric Infect Dis Soc. 2022;11(5):177-85. DOI: 10.1093/jpids/piab124; PMCID: PMC8903349; PMID: 35107571
Sarrell BA, Bloch K, El Chediak A, Kumm K, Tracy K, Forbes RC, et al. Monoclonal antibody treatment for COVID-19 in solid organ transplant recipients. Transpl Infect Dis. 2022;24(1):e13759. DOI: 10.1111/tid.13759; PMCID: PMC8646855; PMID: 34787345
Webb BJ, Buckel W, Vento T, Butler AM, Grisel N, Brown SM, et al. Real-world Effectiveness and Tolerability of Monoclonal Antibody Therapy for Ambulatory Patients With Early COVID-19. Open Forum Infect Dis. 2021;8(7):ofab331. DOI: 10.1093/ofid/ofab331; PMCID: PMC8314951; PMID: 34327256
Corti D, Purcell LA, Snell G, Veesler D. Tackling COVID-19 with neutralizing monoclonal antibodies. Cell. 2021;184(12):3086-108. DOI: 10.1016/j.cell.2021.05.005; PMCID: PMC8152891; PMID: 34087172
McCreary EK, Bariola JR, Wadas RJ, Shovel JA, Wisniewski MK, Adam M, et al. Association of Subcutaneous or Intravenous Administration of Casirivimab and Imdevimab Monoclonal Antibodies With Clinical Outcomes in Adults With COVID-19. JAMA Netw Open. 2022;5(4):e226920. DOI: 10.1001/jamanetworkopen.2022.6920; PMCID: PMC9006104; PMID: 35412625
Isa F, Ortiz AMG, Meyer J, Hamilton JD, Olenchock BA, Brackin T, et al. Effect of timing of casirivimab and imdevimab administration relative to mRNA-1273 COVID-19 vaccination on vaccine-induced SARS-CoV-2 neutralising antibody responses: a prospective, open-label, phase 2, randomised controlled trial. Lancet Infect Dis. 2024;S1473-3099(24)00421-3. DOI: 10.1016/s1473-3099(24)00421-3; PMID: 39236733
Kreuzberger N, Hirsch C, Andreas M, Böhm L, Bröckelmann PJ, Di Cristanziano V, et al. Immunity after COVID-19 vaccination in people with higher risk of compromised immune status: a scoping review. Cochrane Database Syst Rev. 2022;8(8):CD01521. DOI: 10.1002/14651858.cd015021; PMCID: PMC9361430; PMID: 35943061
Smati S, Tramunt B, Wargny M, Caussy C, Gaborit B, Vatier C, et al. Relationship between obesity and severe COVID-19 outcomes in patients with type 2 diabetes: Results from the CORONADO study. Diabetes Obes Metab. 2021;23(2):391-403. DOI: 10.1111/dom.14228; PMCID: PMC7675375; PMID: 33051976
Huang Y, Yang C, Xu XF, Xu W, Liu SW. Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. Acta Pharmacol Sin. 2020;41(9):1141-9. DOI: 10.1038/s41401-020-0485-4; PMCID: PMC7396720; PMID: 32747721
Suvarnapathaki S, Chauhan D, Nguyen A, Ramalingam M, Camci-Unal G. Advances in Targeting ACE2 for Developing COVID-19 Therapeutics. Ann Biomed Eng. 2022;50(12):1734-49. DOI: 10.1007/s10439-022-03094-w; PMCID: PMC9581451; PMID: 36261668
Quinteros DA, Bermúdez JM, Ravetti S, Cid A, Allemandi A, Palma SD. Therapeutic use of monoclonal antibodies: general aspects and challenges for drug delivery. In: Andronescu E, Grumezescu AM, editors. Nanostructures for Drug Delivery. Amsterdam: Elsevier; 2017. DOI: 10.1016/B978-0-323-46143-6.00025-7; PMCID: PMC7151974
Zhou D, Zhou R, Chen Z. Human neutralizing antibodies for SARS-CoV-2 prevention and immunotherapy. Immunother Adv. 2021;2(1):ltab027. DOI: 10.1093/immadv/ltab027; PMCID: PMC8755319; PMID: 35915816
Mitra S, Tomar PC. Hybridoma technology; advancements, clinical significance, and future aspects. J Genet Eng Biotechnol. 2021;19(1):159. DOI: 10.1186/s43141-021-00264-6; PMCID: PMC8521504; PMID: 34661773
Zahavi D, Weiner L. Monoclonal Antibodies in Cancer Therapy. Antibodies. 2020;9(3):34. DOI: 10.3390/antib9030034; PMCID: PMC7551545; PMID: 32698317
Andrews NP, Boeckman JX, Manning CF, Nguyen JT, Bechtold H, Dumitras C, et al. A toolbox of IgG subclass-switched recombinant monoclonal antibodies for enhanced multiplex immunolabeling of brain. Elife. 2019;8:e43322. DOI: 10.7554/elife.43322; PMCID: PMC6377228; PMID: 30667360
Pinto D, Park YJ, Beltramello M, Walls AC, Tortorici MA, Bianchi S, et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature. 2020;583(7815):290-5. DOI: 10.1038/s41586-020-2349-y; PMID: 32422645
Shrestha J, Sherchan R. Bamlanivimab. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024. NBKID: NBK576376
Tai YL, Lee MD, Chi H, Chiu NC, Lei WT, Weng SL, et al. Effects of bamlanivimab alone or in combination with etesevimab on subsequent hospitalization and mortality in outpatients with COVID-19: a systematic review and meta-analysis. PeerJ. 2023;11:e15344. DOI: 10.7717/peerj.15344; PMCID: PMC10174063; PMID: 37180576
Eroglu B, Nuwarda RF, Ramzan I, Kayser V. A Narrative Review of COVID-19 Vaccines. Vaccines. 2021;10(1):62. DOI: 10.3390/vaccines10010062; PMCID: PMC8779282; PMID: 35062723
Esposito S, Amirthalingam G, Bassetti M, Blasi F, De Rosa FG, Halasa NB, et al. Monoclonal antibodies for prophylaxis and therapy of respiratory syncytial virus, SARS-CoV-2, human immunodeficiency virus, rabies and bacterial infections: an update from the World Association of Infectious Diseases and Immunological Disorders and the Italian Society of Antinfective Therapy. Front Immunol. 2023;14:1162342. DOI: 10.3389/fimmu.2023.1162342; PMCID: PMC10226646; PMID: 37256125
Baldo BA. Immune- and Non-Immune-Mediated Adverse Effects of Monoclonal Antibody Therapy: A Survey of 110 Approved Antibodies. Antibodies. 2022;11(1):17. DOI: 10.3390/antib11010017; PMCID: PMC8944650; PMID: 35323191
Gopalaswamy R, Aravindhan V, Subbian S. The Ambivalence of Post COVID-19 Vaccination Responses in Humans. Biomolecules. 2024;14(10):1320. DOI: 10.3390/biom14101320; PMCID: PMC11506738; PMID: 39456253
Chen Z, Zhang P, Matsuoka Y, Tsybovsky Y, West K, Santos C, et al. Potent monoclonal antibodies neutralize Omicron sublineages and other SARS-CoV-2 variants. Cell Rep. 2022;41(5):111528. DOI: 10.1016/j.celrep.2022.111528; PMCID: PMC9554601; PMID: 36302375
Sapir T, Averch Z, Lerman B, Bodzin A, Fishman Y, Maitra R. COVID-19 and the Immune Response: A Multi-Phasic Approach to the Treatment of COVID-19. Int J Mol Sci. 2022;23(15):8606. DOI: 10.3390/ijms23158606; PMCID: PMC9369212; PMID: 35955740
Cox M, Peacock TP, Harvey WT, Hughes J, Wright DW, COVID-19 Genomics UK (COG-UK) Consortium, et al. SARS-CoV-2 variant evasion of monoclonal antibodies based on in vitro studies. Nat Rev Microbiol. 2023;21(2):112-24. DOI: 10.1038/s41579-022-00809-7; PMCID: PMC9616429; PMID: 36307535
Cho H, Gonzales-Wartz KK, Huang D, Yuan M, Peterson M, Liang J, et al. Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern. Sci Transl Med. 2021;13(616):eabj5413. DOI: 10.1126/scitranslmed.abj5413; PMCID: PMC8651051; PMID: 34519517
Yilmaz O, Torres T. Extended Half-life Antibodies: A Narrative Review of a New Approach in the Management of Atopic Dermatitis. Dermatol Ther. 2024;14(9):2393-406. DOI: 10.1007/s13555-024-01253-6; PMCID: PMC11393227; PMID: 39147994
Hillary VE, Ceasar SA. An update on COVID-19: SARS-CoV-2 variants, antiviral drugs, and vaccines. Heliyon. 2023;9(3):e13952. DOI: 10.1016/j.heliyon.2023.e13952; PMCID: PMC9946785; PMID: 36855648
Shyr ZA, Cheng YS, Lo DC, Zheng W. Drug combination therapy for emerging viral diseases. Drug Discov Today. 2021;26(10):2367-76. DOI: 10.1016/j.drudis.2021.05.008; PMCID: PMC8139175; PMID: 34023496
Wang R, Guo J, Lu J, Du P, Zhang J, Yu Y, et al. A potential broad-spectrum neutralizing antibody against Betacoronavirus. J Med Virol. 2023;95(12):e29252. DOI: 10.1002/jmv.29252; PMID: 38078658
Passariello M, Gentile C, Ferrucci V, Sasso E, Vetrei C, Fusco G, et al. Novel human neutralizing mAbs specific for Spike-RBD of SARS-CoV-2. Sci Rep. 2021;11(1):11046. DOI: 10.1038/s41598-021-90348-7; PMCID: PMC8155001; PMID: 34040046
Cruz-Teran C, Tiruthani K, McSweeney M, Ma A, Pickles R, Lai SK. Challenges and opportunities for antiviral monoclonal antibodies as COVID-19 therapy. Adv Drug Deliv Rev. 2021;169:100-17. DOI: 10.1016/j.addr.2020.12.004; PMCID: PMC7833882; PMID: 33309815
Akram F, Ali AM, Akhtar MT, Fatima T, Shabbir I, Haq IU. The journey of antibody-drug conjugates for revolutionizing cancer therapy: A review. Bioorg Med Chem. 2024;117:118010. DOI: 10.1016/j.bmc.2024.118010; PMID: 39586174
Fu Z, Li S, Han S, Shi C, Zhang Y. Antibody drug conjugate: the "biological missile" for targeted cancer therapy. Signal Transduct Target Ther. 2022;7(1)93. DOI: 10.1038/s41392-022-00947-7; PMCID: PMC8941077; PMID: 35318309
Downloads
Published
Issue
Section
Categories
License
Copyright (c) 2024 Saurabh Nimesh, Pratibha Kumari, Rohit Kumar, Gosiya Gosiya, Md. Quamuddin, Md. Iftekhar Ahmad
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Authors continue to retain the copyright to the article if the article is published in the Borneo Journal of Pharmacy. They will also retain the publishing rights to the article without any restrictions.
Authors who publish in this journal agree to the following terms:
- Any article on the copyright is retained by the author(s).
- The author grants the journal the right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share work with an acknowledgment of the work authors and initial publications in this journal.
- Authors can enter into separate, additional contractual arrangements for the non-exclusive distribution of published articles (e.g., post-institutional repository) or publish them in a book, with acknowledgment of their initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their websites) prior to and during the submission process. This can lead to productive exchanges and earlier and greater citations of published work.
- The article and any associated published material are distributed under the Creative Commons Attribution-ShareAlike 4.0 International License.